Cargando…

Midlife brain metastases in the United States: Is male at risk?

BACKGROUND: Population‐based estimates of the impact of gender throughout the whole course of brain metastases (BMs) at the time of diagnosis of systemic malignancies are insufficient. We aimed to discover the influence of gender on the presence of BMs in newly diagnosed malignancies and the surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Wenqiang, Wang, Yujiao, Wang, Xiangyu, Lyu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855893/
https://www.ncbi.nlm.nih.gov/pubmed/35019232
http://dx.doi.org/10.1002/cam4.4499
_version_ 1784653733250990080
author Che, Wenqiang
Wang, Yujiao
Wang, Xiangyu
Lyu, Jun
author_facet Che, Wenqiang
Wang, Yujiao
Wang, Xiangyu
Lyu, Jun
author_sort Che, Wenqiang
collection PubMed
description BACKGROUND: Population‐based estimates of the impact of gender throughout the whole course of brain metastases (BMs) at the time of diagnosis of systemic malignancies are insufficient. We aimed to discover the influence of gender on the presence of BMs in newly diagnosed malignancies and the survival of those patients on a population‐based level. METHODS: Midlife patients (40 years ≤ age ≤60 years) with newly diagnosed malignancies and BMs at the time of diagnosis were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Clinical variables adjusted patient data. The LASSO regression was performed to exclude the possibility of collinearity. Univariable and multivariable logistic regression analyses were applied to find independent predictors for the presence of BMs, while univariable and multivariable Cox proportional hazard regression analyses were used to determine prognosticators of survival. K‐M curves were used to perform the survival analysis. RESULT: 276,327 population‐based samples met inclusion criteria between 2014 and 2016, and 5747 (2.08%) patients were diagnosed with BMs at the time of diagnosis of systematic malignancies. Among all midlife patients with cancer, 44.02% (121,634) were male, while 51.68% (2970) were male among patients with BMs at the time of diagnosis. The most frequent tumor type was breast cancer (23.11%), and lung cancer had the highest incidence proportion of BMs among the entire cohort (19.34%). The multivariable logistic regression model suggested that female (vs. male, odds ratio [OR] 1.07, 95% CI: 1.01–1.14, p < 0.001) was associated with a higher risk of the presence of BMs at the time of diagnosis. Moreover, in the multivariable Cox model for all‐cause mortality in individuals with BMs at diagnosis, female (vs. male, hazard ratio [HR], 0.86, 95% CI, 0.80–0.92, p < 0.001) was shown to have a lower risk of decreased all‐cause mortality. CONCLUSION: The middle‐aged females were at increased risk of developing BMs, while the middle‐aged males with BMs were at higher risk of having poorer survival.
format Online
Article
Text
id pubmed-8855893
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88558932022-02-25 Midlife brain metastases in the United States: Is male at risk? Che, Wenqiang Wang, Yujiao Wang, Xiangyu Lyu, Jun Cancer Med Cancer Prevention BACKGROUND: Population‐based estimates of the impact of gender throughout the whole course of brain metastases (BMs) at the time of diagnosis of systemic malignancies are insufficient. We aimed to discover the influence of gender on the presence of BMs in newly diagnosed malignancies and the survival of those patients on a population‐based level. METHODS: Midlife patients (40 years ≤ age ≤60 years) with newly diagnosed malignancies and BMs at the time of diagnosis were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute. Clinical variables adjusted patient data. The LASSO regression was performed to exclude the possibility of collinearity. Univariable and multivariable logistic regression analyses were applied to find independent predictors for the presence of BMs, while univariable and multivariable Cox proportional hazard regression analyses were used to determine prognosticators of survival. K‐M curves were used to perform the survival analysis. RESULT: 276,327 population‐based samples met inclusion criteria between 2014 and 2016, and 5747 (2.08%) patients were diagnosed with BMs at the time of diagnosis of systematic malignancies. Among all midlife patients with cancer, 44.02% (121,634) were male, while 51.68% (2970) were male among patients with BMs at the time of diagnosis. The most frequent tumor type was breast cancer (23.11%), and lung cancer had the highest incidence proportion of BMs among the entire cohort (19.34%). The multivariable logistic regression model suggested that female (vs. male, odds ratio [OR] 1.07, 95% CI: 1.01–1.14, p < 0.001) was associated with a higher risk of the presence of BMs at the time of diagnosis. Moreover, in the multivariable Cox model for all‐cause mortality in individuals with BMs at diagnosis, female (vs. male, hazard ratio [HR], 0.86, 95% CI, 0.80–0.92, p < 0.001) was shown to have a lower risk of decreased all‐cause mortality. CONCLUSION: The middle‐aged females were at increased risk of developing BMs, while the middle‐aged males with BMs were at higher risk of having poorer survival. John Wiley and Sons Inc. 2022-01-12 /pmc/articles/PMC8855893/ /pubmed/35019232 http://dx.doi.org/10.1002/cam4.4499 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Che, Wenqiang
Wang, Yujiao
Wang, Xiangyu
Lyu, Jun
Midlife brain metastases in the United States: Is male at risk?
title Midlife brain metastases in the United States: Is male at risk?
title_full Midlife brain metastases in the United States: Is male at risk?
title_fullStr Midlife brain metastases in the United States: Is male at risk?
title_full_unstemmed Midlife brain metastases in the United States: Is male at risk?
title_short Midlife brain metastases in the United States: Is male at risk?
title_sort midlife brain metastases in the united states: is male at risk?
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855893/
https://www.ncbi.nlm.nih.gov/pubmed/35019232
http://dx.doi.org/10.1002/cam4.4499
work_keys_str_mv AT chewenqiang midlifebrainmetastasesintheunitedstatesismaleatrisk
AT wangyujiao midlifebrainmetastasesintheunitedstatesismaleatrisk
AT wangxiangyu midlifebrainmetastasesintheunitedstatesismaleatrisk
AT lyujun midlifebrainmetastasesintheunitedstatesismaleatrisk